Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below 200-Day Moving Average - Here's Why

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $14.13 and traded as low as $13.74. Arcturus Therapeutics shares last traded at $14.41, with a volume of 517,333 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. BTIG Research set a $48.00 price objective on Arcturus Therapeutics and gave the stock a "buy" rating in a research note on Monday, March 10th. Wall Street Zen upgraded Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. Scotiabank assumed coverage on shares of Arcturus Therapeutics in a report on Wednesday, May 28th. They set a "sector outperform" rating and a $32.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $60.00 target price on shares of Arcturus Therapeutics in a report on Thursday, April 10th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $53.50.

Arcturus Therapeutics Trading Down 2.4%

The company has a market cap of $352.83 million, a P/E ratio of -5.14 and a beta of 2.30. The company has a quick ratio of 5.64, a current ratio of 5.64 and a debt-to-equity ratio of 0.06. The firm's 50-day moving average price is $12.40 and its 200-day moving average price is $14.02.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($1.58) by $1.06. The firm had revenue of $29.38 million for the quarter, compared to analysts' expectations of $25.64 million. Arcturus Therapeutics had a negative return on equity of 27.41% and a negative net margin of 47.47%. As a group, equities research analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Arcturus Therapeutics

Hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. increased its holdings in shares of Arcturus Therapeutics by 5.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 207,802 shares of the biotechnology company's stock worth $3,526,000 after buying an additional 10,180 shares during the last quarter. Tocqueville Asset Management L.P. grew its position in Arcturus Therapeutics by 42.7% in the fourth quarter. Tocqueville Asset Management L.P. now owns 22,400 shares of the biotechnology company's stock worth $380,000 after acquiring an additional 6,700 shares in the last quarter. American Century Companies Inc. increased its stake in Arcturus Therapeutics by 10.7% in the fourth quarter. American Century Companies Inc. now owns 47,018 shares of the biotechnology company's stock valued at $798,000 after acquiring an additional 4,547 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in Arcturus Therapeutics in the fourth quarter valued at $71,000. Finally, Vanguard Group Inc. raised its position in Arcturus Therapeutics by 6.8% during the fourth quarter. Vanguard Group Inc. now owns 1,684,561 shares of the biotechnology company's stock valued at $28,587,000 after purchasing an additional 107,635 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.